Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
27.71
+0.78 (2.90%)
At close: Sep 11, 2025, 4:00 PM EDT
27.71
0.00 (0.00%)
After-hours: Sep 11, 2025, 4:34 PM EDT
Alkermes Employees
Alkermes had 1,800 employees as of December 31, 2024. The number of employees decreased by 300 or -14.29% compared to the previous year.
Employees
1,800
Change (1Y)
-300
Growth (1Y)
-14.29%
Revenue / Employee
$836,276
Profits / Employee
$193,581
Market Cap
4.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,800 | -300 | -14.29% |
| Dec 31, 2023 | 2,100 | -180 | -7.89% |
| Dec 31, 2022 | 2,280 | 69 | 3.12% |
| Dec 31, 2021 | 2,211 | -34 | -1.51% |
| Dec 31, 2020 | 2,245 | 10 | 0.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALKS News
- 13 hours ago - Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - PRNewsWire
- 3 days ago - Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript) - Seeking Alpha
- 3 days ago - Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 - PRNewsWire
- 17 days ago - Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PRNewsWire
- 6 weeks ago - Alkermes: A More Than Solid Quarter - Seeking Alpha
- 6 weeks ago - Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Alkermes plc Reports Second Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PRNewsWire